3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Imatinib Mesylate
23
Cyclophosphamide
18
fludarabine
17
fludarabine phosphate
13
Busulfan
12
Whole-Body Irradiation
11
nilotinib
10
Dasatinib
9
thymoglobulin
8
ponatinib
8
Mycophenolic Acid
8
Cytarabine
7
Antilymphocyte Serum
7
peginterferon alfa-2b
6
Tacrolimus
6
Cyclosporine
6
Clofarabine
6
Thiotepa
5
Stem Cell Transplantation
4
Sirolimus
4
Rituximab
4
Peripheral Blood Stem Cell Transplantation
4
Melphalan
4
Alemtuzumab
4
sargramostim
3
Interferon-alpha
3
Homoharringtonine
3
Cord Blood Stem Cell Transplantation
3
Bortezomib
3
zileuton
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled